COMMITMENT...MATTERS

SCIENTIFIC & MEDICAL PUBLICATIONS

2018 EHA Meeting - TG Therapeutics, Inc. Presents TG-1701 or SHR-1459, a novel, orally available, and covalently-bound BTK inhibitor

2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients."

​2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial."

​2018 ASCO Meeting - ​Hengrui Medicine presents an abstract titled "​Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma."

​2018 ASCO Meeting - ​Hengrui Medicine presents an abstract titled "​Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma."

2017 ASCO Meeting - Hengrui Medicine presents an abstract titled "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors."

2017 Journal of Clinical Oncology - "Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer"

2017 European Journal of Pharmaceutical Sciences - "Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer"